Abstract

Objective: To compare increase in BMD following treatment with salmon calcitonin or zoledronic acid in osteoporosis and to compare the side effects of each drug. Materials and method: 50 patients (25 in each group) who attend the orthopaedics department of RIMS during October 2012 and September 2014 and who fulfil the inclusion criteria are included in the study. The subjects are distributed in two groups, on random basis, one treated with salmon calcitonin and the other group treated with zoledronic acid with equal amount of supplemental calcium and calcitriol combination. A BMD by DEXA scan was measured at the start of therapy, after 6 months of therapy and at the end of 1 year of therapy and the results compared. Statistical analysis was performed using independent T-test value. Result: Zoledronic acid causes better improvement of the bone mass as compared to intra nasal salmon calcitonin in my study.

Authors and Affiliations